Study #2020-0253
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or
MD Anderson Study Status
Not Accepting
Treatment Agent
durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel, durvalumab
Description
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endometrial Neoplasms
Study phase:
Phase III
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-855-807-9574
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.